Navigation Links
EntreMed Reports Second Quarter 2010 Financial Results

ROCKVILLE, Md., Aug. 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six-month periods ending June 30, 2010.  



The Company reported a net loss for the second quarter of 2010 of ($4.9 million), or ($0.62) per share.  This compares with a net loss of ($3.1 million), or ($0.46) per share, for the same period last year.  For the first six months of 2010 the reported net loss was ($7.1 million), or ($0.95) per share as compared to ($6.6 million), or ($0.98) per share for 2009.  

As of June 30, 2010, EntreMed had cash and short-term investments of approximately $8 million.

Ms. Kathy Wehmeir-Davis, EntreMed Principal Accounting Officer, commented on the second quarter results, "During the second quarter, the Company recorded a $3.0 million non-cash charge in connection with a stock milestone payment triggered by the successful initiation of our Phase 2 clinical study with ENMD-2076. Excluding the non-cash charge, second quarter expenses were in line with our expectations and below the comparable period in 2009. We anticipate third and fourth quarter operating expenses to increase slightly as we complete enrollment for the multi-center Phase 2 ovarian cancer study. In addition, we expect that the majority of our 2010 revenue will be from royalties on the sales of Thalomid®, which will be recorded as received."

Michael M. Tarnow, EntreMed Executive Chairman, further commented, "The second quarter of 2010 was pivotal for the Company.  During the second quarter, we achieved a critical milestone with the initiation of the multi-center Phase 2 study for ENMD-2076 in ovarian cancer patients.  The Phase 2 study is being conducted at six prestigious cancer centers within the U.S. and Canada and all sites are currently enrolling patients.  In addition, we regained compliance with the minimum bid price rule and maintained our listing on the NASDAQ Capital Market.  Early in the second quarter we completed our third financing for 2010 for $3.0 million in gross proceeds.  We remain encouraged and enthusiastic about the progress of the ENMD-2076 clinical program and are working hard to meet our development objectives for this exciting compound."

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrated significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. While ENMD-2076 is currently in a Phase 2 trial in ovarian cancer, preclinical and clinical activities are ongoing in assessing the compound's applicability in other forms of cancer.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at and in various filings with the Securities and Exchange Commission.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time.  Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the NASDAQ Capital Market; the volatility of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; the failure to consummate a transaction to monetize the royalty stream for any reason, including our inability to obtain the required third-party consents; declines in actual sales of Thalomid® resulting in reduced revenues; risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

(Financial Table Attached)ENTREMED, INC.SUMMARY OF OPERATING RESULTS(Unaudited)Three Months Ended June 30,2010

2009Total revenues


$0Research and development


1,659,474General and administrative


1,010,733Acquired in-process research and development


0Net loss


(3,051,193)Net loss per share (basic and diluted)


$(0.46)attributable to common shareholders*Weighted average number of shares outstanding


7,180,400(basic and diluted)*Six Months Ended June 30,2010

2009Total revenues


$0Research and development


3,612,934General and administrative


2,170,454Acquired in-process research and development


0Net loss


(6,567,948)Net loss per share (basic and diluted)


$(0.98)attributable to common shareholders*Weighted average number of shares outstanding


7,180,400(basic and diluted)*Cash and short-term investments


$15,154,973*All share and per-share information included in the table above has been restated to reflect retrospective application of the 1-for-11 reverse stock split affected on July 1, 2010.Contact:Ginny DunnAssociate DirectorCorporate Communications & Investor Relations240-864-2643

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
2. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
3. EntreMed Presents Initial Clinical Results for ENMD-2076
4. EntreMed Receives New Patent for 2-Methoxyestradiol Analogs
5. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
6. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
7. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
8. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
9. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
10. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
11. EntreMed to Present at The New York Society of Security Analysts Industry Conference
Post Your Comments:
(Date:10/8/2015)...  The National Heart, Lung and Blood Institute ... Broad Institute of MIT and Harvard to provide ... well as data to support smaller pilots in ... for Precision Medicine (TOPMed) program and serves ... which will use whole genome sequencing to drive ...
(Date:10/8/2015)... 2015 ... "Natural Language Processing Market for Health ... (Rule-Based, Statistical, & Hybrid NLP Solutions), Region ... Africa, Latin America) - Global Forecast to ... --> ) has announced the ...
(Date:10/8/2015)... Oct. 08 2015 ... "Global API Market Outlook 2020" report ... has announced the addition of the "Global ... offering. --> Research and Markets ( ... "Global API Market Outlook 2020" report ...
Breaking Medicine Technology:
... Aug. 31, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... three upcoming investor conferences.  Dr. Mark A. Sirgo, President ... where he will focus on BDSI,s product pipeline, particularly ... which data from the pivotal Phase 3 efficacy study ...
... 2011 Elbit Imaging Ltd. (NASDAQ: EMITF) ... placed an Investor Relations Presentation relating to its Sources and ... "Investor Relations - Company Presentations -Analysis of Sources and Uses." ... Imaging Ltd. operates in the following principal fields of business: ...
Cached Medicine Technology:
(Date:10/10/2015)... ... 2015 , ... Story Chaser is a one-of-a-kind app that makes ... and inspiring stories and as words drop down and users tap the corresponding word. ... and can be interacted with, making it a more engaging game. Users can use ...
(Date:10/9/2015)... ... ... Doctors on Liens has teamed up with a renowned medical practice, ... to personal injury victims. When personal injury victims suffer major, complex injuries, they ... of conditions ailing them. With the addition of this new group of doctors ...
(Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is ... – just in time for the cold and flu season, which the Center for ... the U.S., the real start of cold/flu season is the start of the school ...
(Date:10/9/2015)... ... 2015 , ... Head Over Heels Athletic Arts gymnast, Madelyn Williams, will attend ... Ranch in Huntsville, Texas on October 17-21. , "It's very exciting to be ... and executive director, said. “It's a stepping stone into the U.S. elite system where ...
(Date:10/9/2015)... Orleans, LA (PRWEB) , ... October 09, 2015 ... ... with offices serving New Orleans and the surrounding communities, is initiating a combined ... and medical care for unwanted animals in southern Louisiana. , Animal Rescue ...
Breaking Medicine News(10 mins):
... from exposure to medications, chemicals and other agentsSAN DIEGO, ... taking cold medication or using certain cleaning products can ... A new Web site ( ) ... latest information about the potential risks of exposure to ...
... restore sight, experts suggest , , THURSDAY, March 5 (HealthDay ... in two forms of childhood blindness has been identified ... of the link between the retinal gene SPATA7 and ... because it pinpoints a new retinal metabolic disease pathway ...
... 100 property and casualty insurers closed 2008 with net ... while the top 100 life insurers suffered unprecedented unrealized ... 2008 Top 100 Performance Monitor revealed a 67.7 percent ... industry,s top property and casualty insurers, from $48.8 billion ...
... Americas, Europe and Asia to Realize New Executive ... Tokyo Stock Exchange), a leading medical diagnostics ... announced executive leadership changes at Sysmex Corporate and ... Effective April 1, 2009, Kazuya Obe will ...
... stroke and heart disease are potential complications of type ... Americans. Now research from Tel Aviv University has found ... a risk factor accelerating cognitive decline and dementia. ... TAU,s Sackler School of Medicine, found that people with ...
... 2009 Many doctors don,t offer emergency contraception ... during emergency department visits because of misinformation about ... by The Children,s Hospital of Philadelphia. , ... reduce unintended pregnancy, the study,s authors said. ...
Cached Medicine News:
Symbia T6, a True Point SPECT·CT system, combines a dual-detector variable angle gamma camera with a six slice CT scanner for advanced oncology, neurology, and cardiology applications....
... ACOM.PC turns every standard PC into ... internists, and cardiologists can use their ... access to image data thanks to ... 3 format and the compatible storage ...
... Soarian Cardiovascular Enterprise is a comprehensive ... care continuum from admission to follow-up. ... image acquisition, and diagnostic tools from ... provide a single, longitudinal clinical repository ...
... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
Medicine Products: